Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentoxyverine is a non-opioid centrally acting antitussive (cough suppressant) used to relieve cough associated with the common cold, flu, bronchitis, and sinusitis. It is available as an active ingredient in over-the-counter cough suppressants either alone or in combination with other agents such as guaifenesin and H1-receptor antagonists. Pentoxyverine exhibits antimuscarinic (anticholinergic), anticonvulsant, spasmolytic, bronchodilating, and local anesthetic properties. Its primary mechanism of action involves agonism at sigma-1 receptors in the central nervous system; it also acts as an antagonist at muscarinic receptors (notably M1 subtype). The drug suppresses the cough reflex by acting on the cough center in the brainstem. Unlike opioid antitussives such as codeine, pentoxyverine does not cause withdrawal symptoms and has a lower risk of respiratory depression[2][3][6]. The FDA has withdrawn oral gel formulations containing pentoxyverine citrate from use in the United States; however other forms remain marketed elsewhere[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentoxyverine.